|
|
|
|
|
05.07.25 - 10:21
|
Dieses Risiko der Online-Apotheken sollten Kunden kennen (Die Welt)
|
|
|
Anbieter wie Shop Apotheke oder DocMorris beliefern deutsche Kunden aus den Niederlanden mit Waren. Bei Lieferungen aus dem Ausland ist die Kühlung der Arzneimittel jedoch nicht sichergestellt. Die Unternehmen widersprechen zwar. Aber eine Garantie haben Kunden nicht....
|
|
|
|
|
|
|
|
|
|
|
03.07.25 - 09:06
|
DAX vor Jobdaten im Plus – Aixtron, Continental, Grenke, K+S, Kion, Nordex, Redcare Pharmacy, Sartorius im Check (Der Aktionaer)
|
|
|
Am Donnerstag stehen am Nachmittag die nächsten US-Arbeitsmarktdaten auf der Agenda, die von vielen Marktteilnehmern mit Spannung erwartet werden. Im Vorfeld hält sich der DAX in Schlagdistanz zur wichtigen 24.000-Punkte-Marke. Unternehmensseitig stehen unter anderen Aixtron, Continental, Grenke, K+S, Kion, Nordex, Redcare Pharmacy und Sartorius im Fokus....
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.25 - 20:30
|
Atai Life Sciences: NBC-Trader sacken +26% in Kürze ein! (Sharedeals)
|
|
|
Einmal mehr demonstriert Chefanalyst Maximilian Ruth sein Können und liefert Mitgliedern des No Brainer Club mit der Aktie von Atai Life Sciences satte zweistellige Kursgewinne in Windeseile. Empfehlung unter 2,30 US$ Die vorbörsliche Kaufempfehlung gab es für NBC-Mitglieder komfortabel um 12:45 Uhr per Push direkt aufs Smartphone. Die Ansage: Kaufen bis 2,30 US$. In der […]
The post Atai Life Sciences: NBC-Trader sacken +26% in Kürze ein! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
01.07.25 - 12:09
|
atai Life Sciences Announces $50 Million Private Placement Financing (GlobeNewswire EN)
|
|
|
Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1 Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1...
|
|
|
01.07.25 - 12:03
|
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire EN)
|
|
|
NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop highly effective mental health treatments to transform patient outcomes, and Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biopharmaceutical company pioneering the next generation of mental health treatments, today jointly announced positive topline results from the eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial evaluating the efficacy and safety of a single dose of BPL-003 (intranasal mebufotenin (5-MeO-DMT) benzoate) in patients with treatment-resistant depression (TRD). The study achieved its primary endpoint as well as all key secondary endpoints. At Day 29, a single 12 mg dose of BPL-003 demonstrated a statistically significant reduction in depressive symptoms, as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), ...
|
|
|
|
|
01.07.25 - 07:33
|
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application (GlobeNewswire EN)
|
|
|
EINDHOVEN, the Netherlands, July 01, 2025 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD and US OTCQX: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities, today announced the submission of two major regulatory applications for its ARC-EX System. The Company has submitted a 510(k) application to the US Food and Drug Administration (FDA) seeking clearance to expand its indication for home use. In parallel, ONWARD has filed an application with the notified body for CE Mark certification in accordance with the European Union Medical Device Regulation (MDR) to enable commercialization of the ARC-EX System in the EU. Completed in June, these submissions represent significant milestones as the Company advances its mission to bring breakthrough therapies to people with SCI around the world....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
